Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $517.03.
ELV has been the subject of several analyst reports. Argus reissued a “hold” rating and set a $405.40 price target on shares of Elevance Health in a report on Wednesday, January 29th. Stephens downgraded shares of Elevance Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $520.00 to $440.00 in a report on Wednesday, January 22nd. Barclays boosted their price target on shares of Elevance Health from $501.00 to $512.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $485.00 price objective on shares of Elevance Health in a report on Friday, January 24th. Finally, Wells Fargo & Company reduced their price objective on shares of Elevance Health from $483.00 to $478.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th.
View Our Latest Report on Elevance Health
Elevance Health Stock Up 1.1 %
Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. Research analysts predict that Elevance Health will post 33.96 EPS for the current year.
Elevance Health Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be issued a $1.71 dividend. This represents a $6.84 dividend on an annualized basis and a yield of 1.62%. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date of this dividend is Monday, March 10th. Elevance Health’s dividend payout ratio is presently 26.71%.
Insider Buying and Selling at Elevance Health
In other Elevance Health news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the sale, the executive vice president now owns 10,116 shares in the company, valued at approximately $4,008,970.80. The trade was a 25.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Ronald W. Penczek sold 443 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $415.13, for a total value of $183,902.59. Following the sale, the chief accounting officer now owns 1,847 shares in the company, valued at approximately $766,745.11. The trade was a 19.34 % decrease in their position. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.
Institutional Trading of Elevance Health
Institutional investors and hedge funds have recently bought and sold shares of the stock. Raelipskie Partnership acquired a new position in shares of Elevance Health in the 3rd quarter valued at about $26,000. Accredited Wealth Management LLC acquired a new position in shares of Elevance Health in the 4th quarter valued at about $25,000. Flagship Wealth Advisors LLC acquired a new position in shares of Elevance Health in the 4th quarter valued at about $26,000. Dunhill Financial LLC increased its holdings in shares of Elevance Health by 57.8% in the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock valued at $37,000 after purchasing an additional 26 shares during the period. Finally, WealthTrak Capital Management LLC acquired a new position in shares of Elevance Health in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 89.24% of the company’s stock.
Elevance Health Company Profile
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Stories
- Five stocks we like better than Elevance Health
- Short Selling – The Pros and Cons
- How to Build the Ultimate Everything ETF Portfolio
- How to Use the MarketBeat Excel Dividend Calculator
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is the Dow Jones Industrial Average (DJIA)?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.